



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

March 2021





© 2021 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

March 2021

N = 7447



Health Authority	Male	Female	All
FRASER	1458	447	1905
INTERIOR	445	102	547
NORTHERN	139	86	225
VANCOUVER COASTAL	3354	436	3790
VANCOUVER ISLAND	792	160	952
	6188	1231	7419
		Unknown/not stated:	28
		Total:	7447

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2016 - March 2021)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2016 - March 2021)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (March 2016 - March 2021)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (March 2016 - March 2021)






1.6 Percent Distribution of Active Participants by CD4 Count (March 2016 - March 2021)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(March 2016 - March 2021)






1.8 Active and Inactive Participants (March 2016 - March 2021)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (March 2016 - March 2021)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT
(March 2016 - March 2021)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(March 2016 - March 2021)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (March 2016 - March 2021)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(March 2016 - March 2021)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (March 2016 - March 2021)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(March 2016 - March 2021)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (March 2016 - March 2021)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(March 2016 - March 2021)






1.18 Baseline CD4 for Antiretroviral First Starts
(March 2016 - March 2021)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (March 2016 - March 2021)






1.20 Cumulative Resistance Testing Results by Resistance Category (March 2016 - March 2021)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (March 2016 - March 2021)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	5	0	5	2	615	5	<40	4
1988	30	5	0	5	3	650	5	<40	3
1989	28	53	1	54	28	515	49	<40	3
1990	26	54	1	55	33	510	53	<40	3
1991	27	37	3	40	20	690	36	<40	3
1992	26	61	4	65	35	560	64	<40	3
1993	26	124	15	139	93	510	131	<40	3
1994	24	78	10	88	54	590	80	<40	3
1995	24	130	19	149	103	560	144	<40	3
1996	22	318	44	362	225	590	341	<40	3
1997	20	273	32	305	201	600	277	<40	3
1998	19	197	43	240	161	560	214	<40	3
1999	19	157	38	195	126	570	169	<40	3
2000	20	119	31	150	102	615	137	<40	3
2001	19	114	28	142	93	640	129	<40	3
2002	18	127	24	151	103	580	139	<40	3
2003	17	145	28	173	109	610	155	<40	3
2004	16	152	40	192	128	625	175	<40	3
2005	15	185	42	227	157	640	206	<40	3
2006	14	170	40	210	141	630	191	<40	3
2007	13	235	48	283	187	620	249	<40	3
2008	12	282	64	346	249	650	310	<40	3
2009	12	304	63	367	235	650	327	<40	3
2010	10	271	71	342	234	660	300	<40	3
2011	10	328	71	399	261	710	345	<40	3
2012	9	270	61	331	207	730	288	<40	3
2013	8	260	65	325	207	680	279	<40	3
2014	7	276	54	330	190	705	287	<40	3
2015	6	279	45	324	218	745	295	<40	3
2016	5	262	54	316	195	680	268	<40	3
2017	4	212	31	243	166	650	219	<40	3
2018	3	193	51	244	162	705	223	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	2	235	42	277	198	632	245	<40	3
2020	1	204	56	260	202	650	244	<40	3
2021	0	70	9	79	70	495	75	151	3
Total:		6185	1228	7413					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	7358	774	2227	<40	1727	610
FEB-2020	7330	776	1882	<40	1415	620
MAR-2020	7387	768	1628	<40	1207	620
APR-2020	7408	770	767	<40	576	595
MAY-2020	7398	776	1186	<40	891	600
JUN-2020	7374	783	1558	<40	1145	620
JUL-2020	7344	794	1918	<40	1436	610
AUG-2020	7268	791	1848	<40	1330	630
SEP-2020	7248	784	1735	<40	1236	620
OCT-2020	7279	776	1781	<40	1303	630
NOV-2020	7361	764	1857	<40	1267	610
DEC-2020	7364	752	1542	<40	1069	640
JAN-2021	7397	741	1942	<40	1331	637
FEB-2021	7387	748	1786	<40	1183	630
MAR-2021	7447	743	2017	<40	1321	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	635	185	70	354	46	435
FEB-2020	675	173	71	<40	58	480
MAR-2020	632	188	50	<40	32	415
APR-2020	611	204	28	116	22	555
MAY-2020	630	187	42	<50	30	490
JUN-2020	662	181	56	<40	46	480
JUL-2020	729	161	72	<40	56	625
AUG-2020	820	142	75	<40	65	470
SEP-2020	872	137	93	<40	71	610
OCT-2020	866	178	87	<40	74	590
NOV-2020	794	192	78	<40	60	510
DEC-2020	798	187	65	<40	54	430
JAN-2021	782	203	73	<40	54	525
FEB-2021	797	199	70	<40	55	510
MAR-2021	781	252	88	<40	65	630

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2020	7328	635	10	12	183	155	18	13903
FEB-2020	7295	675	12	19	141	172	-33	13939
MAR-2020	7358	632	14	23	210	152	63	13975
APR-2020	7382	611	12	8	158	127	24	14000
MAY-2020	7375	630	10	15	130	135	-7	14025
JUN-2020	7346	662	8	9	125	149	-29	14042
JUL-2020	7309	729	15	12	160	189	-37	14074
AUG-2020	7222	820	18	11	168	241	-87	14094
SEP-2020	7193	872	19	9	228	241	-29	14115
OCT-2020	7227	866	20	13	223	175	34	14136
NOV-2020	7311	794	12	12	244	155	84	14162
DEC-2020	7326	798	10	13	205	190	15	14191
JAN-2021	7364	782	14	10	203	159	38	14211
FEB-2021	7356	797	15	15	184	191	-8	14236
MAR-2021	7413	781	13	24	202	155	57	14272

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2020	60	6758	484	56	7358	0.82%	91.85%	6.58%	0.76%	100.00%
FEB-2020	59	6736	477	58	7330	0.80%	91.90%	6.51%	0.79%	100.00%
MAR-2020	60	6790	487	50	7387	0.81%	91.92%	6.59%	0.68%	100.00%
APR-2020	61	6814	483	50	7408	0.82%	91.98%	6.52%	0.67%	100.00%
MAY-2020	60	6807	481	50	7398	0.81%	92.01%	6.50%	0.68%	100.00%
JUN-2020	59	6779	485	51	7374	0.80%	91.93%	6.58%	0.69%	100.00%
JUL-2020	62	6762	472	48	7344	0.84%	92.08%	6.43%	0.65%	100.00%
AUG-2020	71	6688	458	51	7268	0.98%	92.02%	6.30%	0.70%	100.00%
SEP-2020	86	6653	457	52	7248	1.19%	91.79%	6.31%	0.72%	100.00%
OCT-2020	107	6659	462	51	7279	1.47%	91.48%	6.35%	0.70%	100.00%
NOV-2020	162	6693	457	49	7361	2.20%	90.93%	6.21%	0.67%	100.00%
DEC-2020	180	6674	461	49	7364	2.44%	90.63%	6.26%	0.67%	100.00%
JAN-2021	205	6694	452	46	7397	2.77%	90.50%	6.11%	0.62%	100.00%
FEB-2021	226	6662	448	51	7387	3.06%	90.19%	6.06%	0.69%	100.00%
MAR-2021	250	6682	464	51	7447	3.36%	89.73%	6.23%	0.68%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	2 8%	3402 47%	2 8%	3226 45%	0 0%	34 0%	0 0%	1 0%	9 38%	1024 14%	13 54%	2963 41%	22 92%	3763 52%
FEB-2020	3 8%	3352 47%	3 8%	3180 45%	0 0%	33 0%	0 0%	1 0%	16 44%	1169 16%	17 47%	2825 40%	33 92%	3781 53%
MAR-2020	5 14%	3325 46%	5 14%	3160 44%	1 3%	34 0%	0 0%	1 0%	20 56%	1326 18%	11 31%	2719 38%	30 83%	3855 54%
APR-2020	6 24%	3298 46%	5 20%	3137 43%	1 4%	35 0%	0 0%	0 0%	8 32%	1402 19%	11 44%	2637 37%	19 76%	3888 54%
MAY-2020	1 4%	3273 45%	0 0%	3112 43%	0 0%	36 0%	0 0%	0 0%	13 54%	1481 21%	11 46%	2595 36%	23 96%	3914 54%
JUN-2020	5 29%	3244 45%	5 29%	3082 43%	0 0%	33 0%	0 0%	0 0%	4 24%	1587 22%	8 47%	2519 35%	12 71%	3925 55%
JUL-2020	6 19%	3205 45%	4 13%	3045 43%	2 6%	32 0%	0 0%	0 0%	14 44%	1697 24%	12 38%	2422 34%	26 81%	3946 55%
AUG-2020	3 15%	3154 45%	2 10%	2995 42%	0 0%	31 0%	0 0%	0 0%	11 55%	1763 25%	6 30%	2317 33%	17 85%	3921 55%
SEP-2020	3 14%	3127 44%	2 10%	2966 42%	0 0%	31 0%	0 0%	0 0%	13 62%	1873 26%	5 24%	2227 32%	18 86%	3935 56%
OCT-2020	2 10%	3127 44%	2 10%	2950 42%	0 0%	29 0%	0 0%	0 0%	12 57%	1975 28%	7 33%	2137 30%	19 90%	3967 56%
NOV-2020	7 27%	3170 44%	3 12%	2940 41%	1 4%	30 0%	0 0%	0 0%	11 42%	2073 29%	8 31%	2081 29%	19 73%	4004 56%
DEC-2020	3 10%	3158 44%	3 10%	2902 40%	0 0%	29 0%	0 0%	0 0%	14 48%	2151 30%	12 41%	2022 28%	26 90%	4020 56%
JAN-2021	2 10%	3159 44%	1 5%	2886 40%	0 0%	28 0%	0 0%	0 0%	12 60%	2225 31%	6 30%	1964 27%	18 90%	4052 56%
FEB-2021	2 8%	3142 44%	2 8%	2849 39%	0 0%	27 0%	0 0%	0 0%	17 68%	2301 32%	6 24%	1899 26%	23 92%	4064 56%
MAR-2021	8 22%	3145 43%	7 19%	2836 39%	0 0%	25 0%	0 0%	0 0%	23 64%	2375 33%	5 14%	1861 26%	28 78%	4120 57%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
APR-2020	0 0%	2 0%	0 0%	838 36%	4 80%	1412 60%	1 20%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAY-2020	0 0%	2 0%	1 10%	834 36%	9 90%	1411 60%	0 0%	89 4%	0 0%	0 0%	0 0%	6 0%	0 0%	0 0%
JUN-2020	0 0%	2 0%	2 33%	813 35%	4 67%	1388 61%	0 0%	86 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JUL-2020	0 0%	1 0%	0 0%	782 35%	8 100%	1362 61%	0 0%	81 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
AUG-2020	0 0%	1 0%	1 20%	752 35%	4 80%	1331 62%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
SEP-2020	0 0%	0 0%	1 33%	737 35%	2 67%	1303 61%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
OCT-2020	0 0%	0 0%	0 0%	711 34%	6 100%	1285 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
NOV-2020	0 0%	1 0%	0 0%	696 34%	3 100%	1273 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
DEC-2020	0 0%	1 0%	1 8%	680 33%	11 92%	1287 63%	0 0%	76 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JAN-2021	0 0%	1 0%	0 0%	657 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1265 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	1 0%	3 100%	590 36%	0 0%	202 12%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	536 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 21%
JUN-2020	0 0%	1 0%	2 100%	524 36%	0 0%	189 13%	0 0%	448 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	439 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	501 36%	0 0%	179 13%	0 0%	423 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	410 30%	2 67%	294 22%
OCT-2020	0 0%	9 1%	1 100%	462 35%	0 0%	173 13%	0 0%	402 30%	0 0%	279 21%
NOV-2020	0 0%	10 1%	2 67%	452 35%	0 0%	172 13%	1 33%	393 30%	0 0%	279 21%
DEC-2020	0 0%	11 1%	2 67%	439 35%	0 0%	164 13%	0 0%	383 30%	1 33%	276 22%
JAN-2021	0 0%	11 1%	1 100%	427 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	162 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	1 100%	419 34%	0 0%	162 13%	0 0%	366 30%	0 0%	267 22%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2643 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2623 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2555 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1024 22%	9 69%	2538 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1142 24%	10 42%	2512 54%	5 21%	549 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1221 26%	6 35%	2462 52%	1 6%	517 11%	0 0%	29 1%	0 0%	521 11%
SEP-2020	13 87%	1340 28%	2 13%	2442 51%	0 0%	498 10%	0 0%	29 1%	0 0%	504 11%
OCT-2020	10 59%	1447 30%	5 29%	2430 50%	0 0%	493 10%	0 0%	30 1%	2 12%	495 10%
NOV-2020	8 36%	1548 31%	9 41%	2481 50%	2 9%	482 10%	0 0%	27 1%	3 14%	490 10%
DEC-2020	10 53%	1630 33%	7 37%	2470 49%	2 11%	459 9%	0 0%	27 1%	0 0%	478 10%
JAN-2021	12 80%	1701 34%	3 20%	2466 49%	0 0%	443 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	15 65%	1776 35%	5 22%	2483 49%	3 13%	420 8%	0 0%	24 0%	0 0%	458 9%
MAR-2021	23 72%	1844 35%	9 28%	2498 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2020	1617	21.98	1210	16.44	3562	48.41	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.46	1154	15.74	3644	49.71	85	1.16	58	0.79	816	11.13
MAR-2020	1540	20.85	1134	15.35	3755	50.83	85	1.15	50	0.68	823	11.14
APR-2020	1522	20.55	1129	15.24	3807	51.39	85	1.15	50	0.67	815	11.00
MAY-2020	1512	20.44	1111	15.02	3831	51.78	83	1.12	50	0.68	811	10.96
JUN-2020	1460	19.80	1085	14.71	3883	52.66	83	1.13	51	0.69	812	11.01
JUL-2020	1424	19.39	1059	14.42	3939	53.64	79	1.08	48	0.65	795	10.83
AUG-2020	1380	18.99	1028	14.14	3948	54.32	78	1.07	51	0.70	783	10.77
SEP-2020	1342	18.52	982	13.55	4003	55.23	76	1.05	52	0.72	793	10.94
OCT-2020	1310	18.00	965	13.26	4067	55.87	76	1.04	51	0.70	810	11.13
NOV-2020	1290	17.52	947	12.87	4143	56.28	75	1.02	49	0.67	857	11.64
DEC-2020	1274	17.30	926	12.57	4164	56.55	71	0.96	49	0.67	880	11.95
JAN-2021	1274	17.22	913	12.34	4201	56.79	68	0.92	46	0.62	895	12.10
FEB-2021	1232	16.68	894	12.10	4235	57.33	66	0.89	51	0.69	909	12.31
MAR-2021	1212	16.28	892	11.98	4283	57.51	64	0.86	51	0.68	945	12.69

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	9	3	2	1	0	0	71
OCT-2020	13	2	1	1	3	3	381
NOV-2020	12	0	1	0	2	6	710
DEC-2020	13	3	3	3	0	4	260
JAN-2021	10	1	4	0	1	2	170
FEB-2021	15	0	2	3	5	5	370
MAR-2021	24	4	5	3	4	5	260

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2020	12531	4027
FEB-2020	12561	4043
MAR-2020	12561	4033
APR-2020	12539	4009
MAY-2020	12529	3997
JUN-2020	12507	3975
JUL-2020	12484	3942
AUG-2020	12452	3918
SEP-2020	12414	3889
OCT-2020	12390	3875
NOV-2020	12404	3876
DEC-2020	12381	3837
JAN-2021	12389	3838
FEB-2021	12381	3831
MAR-2021	12386	3826

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
March 2021

N = 7447

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2021

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2021

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2021

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2021

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2021

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	5
	35-49	10	11	6
	50+	27	39	18
	Total HSDA:	43	56	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	98	58	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	397	534	307	
THOMPSON/CARIBOO/ SHUSWAP	20-34	18	18	11
	35-49	67	73	48
	50+	114	186	94
	Total HSDA:	199	277	153
Total HA:		712	965	547

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		712	965	547

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	573	775	445
Female	139	190	102

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	547	56	610	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	21	11
	5 years or more	10	7
	<5 years	12	11
	Total HSDA:	43	29
KOOTENAY BOUNDARY	10 years or more	48	37
	5 years or more	14	10
	<5 years	11	11
	Total HSDA:	73	58
OKANAGAN	10 years or more	245	183
	5 years or more	92	77
	<5 years	60	47
	Total HSDA:	397	307
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	114	87
	5 years or more	44	40
	<5 years	41	26
	Total HSDA:	199	153
Total HA:		712	547

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	428	318
5 years or more	160	134
<5 years	124	95
Total HA:	712	547

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	50	66	16	25
KOOTENAY BOUNDARY	76	126	26	47
OKANAGAN	227	962	57	296
THOMPSON/CARIBOO/SHUSWAP	141	529	37	127
Total:	494	1683	136	495

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	104

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	34	36	27
	35-49	97	106	68
	50+	245	330	189
	Total HSDA:	382	478	290
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1060	1440	795
FRASER SOUTH	0-19	5	5	5
	20-34	114	116	81
	35-49	320	356	261
	50+	575	860	473
	Total HSDA:	1014	1337	820
Total HA:		2456	3255	1905

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	12
	20-34	270	274	189
	35-49	751	822	572
	50+	1423	2147	1132
Total HA:		2456	3255	1905

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1850	2483	1458
Female	606	772	447

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1905	52	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	232	180
	5 years or more	82	59
	<5 years	68	51
	Total HSDA:	382	290
FRASER NORTH	10 years or more	629	456
	5 years or more	243	192
	<5 years	188	147
	Total HSDA:	1060	795
FRASER SOUTH	10 years or more	604	486
	5 years or more	212	162
	<5 years	198	172
	Total HSDA:	1014	820
Total HA:		2456	1905

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1465	1122
	5 years or more	537	413
	<5 years	454	370
Total HA:		2456	1905

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	140	507	28	56
FRASER NORTH	255	1590	48	215
FRASER SOUTH	220	1633	51	494
Total:	615	3730	127	765

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	195
FRASER NORTH	660
FRASER SOUTH	454
Total:	1309

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		340	495
RICHMOND	20-34	34	35	21
	35-49	47	48	37
	50+	111	159	88
	Total HSDA:	192	242	146
VANCOUVER	0-19	11	11	9
	20-34	442	457	283
	35-49	1330	1485	951
	50+	2906	5034	2120
	Total HSDA:	4689	6987	3363
Total HA:		5221	7724	3790

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	10
	20-34	498	514	320
	35-49	1458	1623	1051
	50+	3253	5575	2409
Total HA:		5221	7724	3790

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4615	6783	3354
Female	604	939	436

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3790	54	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	198	162
	5 years or more	81	67
	<5 years	61	52
	Total HSDA:	340	281
RICHMOND	10 years or more	114	83
	5 years or more	34	27
	<5 years	44	36
	Total HSDA:	192	146
VANCOUVER	10 years or more	2993	2074
	5 years or more	1006	744
	<5 years	690	545
	Total HSDA:	4689	3363
Total HA:		5221	3790

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3305	2319
	5 years or more	1121	838
	<5 years	795	633
Total HA:		5221	3790

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	180	405	54	81
RICHMOND	43	292	9	92
VANCOUVER	635	11092	209	5306
Total:	858	11789	272	5479

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	80

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		338	484
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		128	172
SOUTH VANCOUVER ISLAND	20-34	76	80	53
	35-49	190	218	146
	50+	490	782	378
	Total HSDA:	756	1080	577
Total HA:		1222	1736	952

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1222	1736	952

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1009	1432	792
Female	213	304	160

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	952	55	570	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	197	162
	5 years or more	72	54
	<5 years	69	54
	Total HSDA:	338	270
NORTH VANCOUVER ISLAND	10 years or more	80	65
	5 years or more	32	24
	<5 years	16	16
	Total HSDA:	128	105
SOUTH VANCOUVER ISLAND	10 years or more	443	314
	5 years or more	156	135
	<5 years	157	128
	Total HSDA:	756	577
Total HA:		1222	952

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	720	541
	5 years or more	260	213
	<5 years	242	198
Total HA:		1222	952

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	202	896	77	202
NORTH VANCOUVER ISLAND	152	271	47	75
SOUTH VANCOUVER ISLAND	214	1844	40	551
Total:	568	3011	164	828

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	52
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	117
Total:	210

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	42	53	24
NORTH WEST	20-34	5	7	*
	35-49	25	40	*
	50+	42	69	*
	Total HSDA:	72	116	55
NORTHERN INTERIOR	0-19	6	6	*
	20-34	22	24	*
	35-49	63	80	*
	50+	101	170	*
	Total HSDA:	192	280	146
Total HA:		306	449	225

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	31	35	*
	35-49	105	140	*
	50+	164	268	*
Total HA:		306	449	225

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	190	280	139
Female	116	169	86

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	225	51	550	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	25	*
	5 years or more	11	*
	<5 years	6	*
	Total HSDA:	42	24
NORTH WEST	10 years or more	42	29
	5 years or more	19	16
	<5 years	11	10
	Total HSDA:	72	55
NORTHERN INTERIOR	10 years or more	88	68
	5 years or more	60	45
	<5 years	44	33
	Total HSDA:	192	146
Total HA:		306	225

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	155	111
	5 years or more	90	68
	<5 years	61	46
Total HA:		306	225

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	40	62	3	*
NORTH WEST	81	166	17	*
NORTHERN INTERIOR	118	469	16	*
Total:	239	697	36	229

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	8
NORTH WEST	21
NORTHERN INTERIOR	13
Total:	42

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	27	43	17
	THOMPSON/CARIBOO/SHUSWAP	24	48	19
	Total HA:	63	110	47
FRASER	FRASER EAST	38	50	28
	FRASER NORTH	55	92	43
	FRASER SOUTH	81	114	57
	Total HA:	174	256	128
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	21
	RICHMOND	8	13	5
	VANCOUVER	480	883	376
	Total HA:	513	944	402
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	83	42
	NORTH VANCOUVER ISLAND	18	27	15
	SOUTH VANCOUVER ISLAND	40	84	31
	Total HA:	109	194	88
NORTHERN	NORTH EAST	10	14	7
	NORTH WEST	29	62	22
	NORTHERN INTERIOR	73	113	63
	Total HA:	112	189	92
Total:		971	1693	757

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	613	1087	478
Female	358	606	279

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	757	52	510	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Monthly Report

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

